Keros Therapeutics (KROS) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Sionna Therapeutics (SION) over the past year, losing 27.1% versus a loss of 82.8%. Keros Therapeutics is the larger company by market cap ($230.8 million vs $221.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | SION |
|---|---|---|
| Share price | $11.64 | $4.90 |
| Market cap | $230.79M | $221.24M |
| 1-day change | +3.84% | +1.66% |
| YTD return | -42.83% | -88.09% |
| 1-year return | -27.07% | -82.81% |
| 5-year return | -70.15% | — |
| EPS (TTM) | $-3.22 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $54.97 |
| 52-week low | $9.69 | $4.01 |
| Distance from 52-week high | -48.38% | -91.09% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +70.36% | +328.57% |
| Average volume | 196.01K | 2.19M |
| Shares outstanding | 19.83M | 45.15M |
| Employees | 92 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KROS has outperformed SION by 55.7 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
KROS vs SION FAQ
Which is bigger, Keros Therapeutics or Sionna Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $230.79M compared with $221.24M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, KROS or SION?
KROS returned -27.07% over the past 12 months, compared with -82.81% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.